| Status | Suspended |
| Decision | Selected |
| Process | TA |
| Referral date | 01 June 2004 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | 01 January 2100 |
| 2nd appraisal committee meeting | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 August 2006 | This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme. |
| 14 September 2006 |
As you may be aware, the Department of Health and the Welsh Assembly Government asked the Institute to conduct an appraisal of lerdelimumab for glaucoma, and to provide guidance on its use to the NHS in England and Wales. Following receipt of trial data, the manufacturer of lerdelimumab has advised us that they have not applied for regulatory approval in relation to this product. The Institute has therefore decided to remove this appraisal from its work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Fuller ( 020 7067 5896 or email: cathryn.fuller@nice.org.uk). |
For further information on our processes and methods, please see our CHTE processes and methods manual